Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18983302 | 0.78 | LPL (0.39) | LPLLIPGEGFRROCK1IDO1 | |
| SCHEMBL20392597 | 0.78 | LPL (0.41) | LPLLIPGEGFRROCK1 | |
| SCHEMBL17839012 | 0.78 | LPL (0.40) | LPLLIPGEGFRROCK1IDO1 | |
| SCHEMBL29502756 | 0.78 | LPL (0.41) | LPLLIPGEGFRROCK1 | |
| SCHEMBL20392650 | 0.77 | LPL (0.39) | LPLLIPGEGFRROCK1IDO1 | |
| SCHEMBL3304381 | 0.76 | LPL (0.33) | LPLLIPGEGFR | |
| SCHEMBL25292477 | 0.76 | LPL (0.37) | LPLLIPGEGFRROCK1 | |
| SCHEMBL26664165 | 0.76 | LPL (0.37) | LPLLIPGEGFRROCK1IDO1 | |
| SCHEMBL25290602 | 0.76 | LPL (0.37) | LPLLIPGEGFRROCK1 | |
| SCHEMBL25153352 | 0.74 | LPL (0.38) | LPLLIPGEGFRROCK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | LPL 3774/4885LIPG 3175/4885EGFR 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.